Roche Holding | ROG - Operating Expenses


Roche Holding reported CHF18.9B in Operating Expenses for its fiscal semester ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Alcon AG USD 2.78B 370M Jun/2026
Almirall EUR 531.16M 13.76M Jun/2026
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bayer EUR 9.92B 121M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Fresenius EUR 5.24B 19M Sep/2026
Fresenius Medical Care EUR 4.55B 229.7M Sep/2026
Genmab DKK 748M 77M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
GRIFOLS EUR 1.65B 101M Sep/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 55.62M 14.56M Jun/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.97B 630M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 9.88B 325M Sep/2026
Orion EUR 332.3M 12.7M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Philips EUR 4.23B 478M Sep/2026
Recordati EUR 485.55M 8.04M Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
UCB EUR 2.96B 196M Dec/2025